Dexamethasone or Methylprednisolone
PreclinicalSmall molecule
Dexamethasone or Methylprednisolone is one of 38 small molecule programs targeting Hearing Loss. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
37
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
46 competitors in Hearing Loss
#DrugCompanyPhaseTrials
1Cymbalta
Alnylam PharmaceuticalsApproved
Medrol
PfizerApproved
Decadron
AAspen Global Incorporated
Approved
Plaquenil
Alnylam PharmaceuticalsApproved
Cipro
BayerApproved
Actonel
VVitae Pharmaceuticals Inc., an Allergan affiliate
Approved
Rayos
RRoxane Laboratories
Approved
Kenalog
BBausch Health Americas, Inc.
Approved
Acetadote
AArbor Pharmaceuticals, Inc.
Approved
Zonegran
AAzurity Pharmaceuticals
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Hearing Loss1 trial
Intratympanic Steroids for Sudden Hearing Loss
Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·N/A·NCT04129697·30 enrolled
Sources
References
- [1]
- [2]
- [3]
- [4]
Details